Rapport Therapeutics (RAPP) Total Liabilities (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Total Liabilities data on file, last reported at $26.1 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $26.1 million, up 60.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.1 million (up 60.85% YoY), and the FY2025 annual result was $27.8 million, up 192.22% from the prior year.
• Total Liabilities eased to $26.1 million in Q1 2026 per RAPP's latest filing, from $27.8 million in the prior quarter.
• Over five years, Total Liabilities peaked at $39.6 million in Q1 2024 and troughed at $8.0 million in Q3 2024.
• A 4-year average of $18.3 million and a median of $15.3 million in 2023 frame the typical range for Total Liabilities.
• On a YoY basis, Total Liabilities climbed as much as 195.22% in 2025 and fell as far as 59.08% in 2025.
• A 4-year view of Total Liabilities shows it stood at $14.5 million in 2023, then sank by 34.35% to $9.5 million in 2024, then soared by 192.22% to $27.8 million in 2025, then dropped by 6.09% to $26.1 million in 2026.
• Business Quant data shows RAPP's Total Liabilities at $26.1 million in Q1 2026, $27.8 million in Q4 2025, and $23.7 million in Q3 2025.